Women with schizophrenia have a high risk for symptom exacerbation or relapse during pregnancy and thereafter. Relapses are more frequent when antipsychotics are discontinued. This paper describes the case of a 28-year old woman with schizophrenia who continued treatment with olanzapine during the first trimester. Olanzapine, a second-generation antipsychotic, was administered at a therapeutic dose from week 1 of gestation until week 13 when she reported the pregnancy to her psychiatrist. Despite the psychiatrist\u27s recommendation to continue treatment, the patient stopped olanzapine at 20 weeks. She was hospitalized at week 36 for a schizophrenia relapse and was transferred to the obstetrics department where she gave birth by Cesarean se...
Unplanned pregnancies in women with psychiatric illness are common and result in exposure of the fet...
Copyright © 2013 Corrado Barbui et al.This is an open access article distributed under the Creative ...
There is no doubt that women and clinicians are in an evidence-free zone when it comes to the risks ...
Petru Ifteni,1,2 Marius A Moga,1 Victoria Burtea,1,2 Christoph U Correll3,4 1Faculty of Medicine, T...
Abstract Background The choice of antipsychotic treatment during pregnancy remains controversial, ma...
AbstractBackgroundWomen prescribed antipsychotics face the dilemma on whether to continue medication...
Objective: To summarize risks related to (1) illness and (2) secondgeneration antipsychotic (SGA) tr...
Objective: To summarize risks related to (1) illness and (2) secondgeneration antipsychotic (SGA) tr...
OBJECTIVE: To summarize risks related to (1) illness and (2) second-generation antipsychotic (SGA) ...
Clinical reports indicate that atypical antipsychotics are associated with a lower incidence of adve...
chotic medication during pregnancy and lactation is associated with increased risks of teratogenic, ...
Pregnant women constitute a vulnerable population, with 25.3% of pregnant women classified as suffer...
Information on neurodevelopmental effects of antenatal exposure to antipsychotics is limited to 10 s...
BACKGROUND: Women prescribed antipsychotics face the dilemma on whether to continue medication in pr...
Background: As a general rule, medical professionals agree that it is best to avoid all drugs during...
Unplanned pregnancies in women with psychiatric illness are common and result in exposure of the fet...
Copyright © 2013 Corrado Barbui et al.This is an open access article distributed under the Creative ...
There is no doubt that women and clinicians are in an evidence-free zone when it comes to the risks ...
Petru Ifteni,1,2 Marius A Moga,1 Victoria Burtea,1,2 Christoph U Correll3,4 1Faculty of Medicine, T...
Abstract Background The choice of antipsychotic treatment during pregnancy remains controversial, ma...
AbstractBackgroundWomen prescribed antipsychotics face the dilemma on whether to continue medication...
Objective: To summarize risks related to (1) illness and (2) secondgeneration antipsychotic (SGA) tr...
Objective: To summarize risks related to (1) illness and (2) secondgeneration antipsychotic (SGA) tr...
OBJECTIVE: To summarize risks related to (1) illness and (2) second-generation antipsychotic (SGA) ...
Clinical reports indicate that atypical antipsychotics are associated with a lower incidence of adve...
chotic medication during pregnancy and lactation is associated with increased risks of teratogenic, ...
Pregnant women constitute a vulnerable population, with 25.3% of pregnant women classified as suffer...
Information on neurodevelopmental effects of antenatal exposure to antipsychotics is limited to 10 s...
BACKGROUND: Women prescribed antipsychotics face the dilemma on whether to continue medication in pr...
Background: As a general rule, medical professionals agree that it is best to avoid all drugs during...
Unplanned pregnancies in women with psychiatric illness are common and result in exposure of the fet...
Copyright © 2013 Corrado Barbui et al.This is an open access article distributed under the Creative ...
There is no doubt that women and clinicians are in an evidence-free zone when it comes to the risks ...